revenue $85.3M, net income -$74.9M. Standard BioTools sells SomaScan proteomics to Illumina, exits clinical testing

Filed March 16, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 11, 2025 · ~2 min read

Key Changes

• high

  Sold entire SomaScan aptamer proteomics business (SomaLogic, Sengenics, KREX) to Illumina for up to $425M ($350M upfront + $75M earnout), closing Jan 30, 2026. Retained only mass cytometry and microfluidics platforms.

  Business: SomaScan divestiture verify on EDGAR →
• high

  Consolidated R&D into Singapore, relocated headquarters from South San Francisco to Boston, and cut ~20% of global workforce in two restructuring actions (Aug/Sep 2025) to align costs with continuing operations.

  MD&A: Restructuring verify on EDGAR →
• high

  Revenue fell 6% to $85.3M in FY2025 vs FY2024, driven by consumables down $4.3M (macroeconomic pressures, budgetary constraints) and services down $1.9M (improved instrument reliability).

  MD&A: Revenue decline verify on EDGAR →